GW Pharmaceuticals PLC (GWPH) Getting Somewhat Favorable Media Coverage, Report Shows
News articles about GW Pharmaceuticals PLC (NASDAQ:GWPH) have been trending somewhat positive recently, according to Accern. The research firm scores the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. GW Pharmaceuticals PLC earned a news sentiment score of 0.15 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 45.3698425728564 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the headlines that may have impacted Accern Sentiment’s rankings:
- Zogenix – Share Offering And Double Top Reversal (seekingalpha.com)
- Vitality Biopharma Stock: Targets Pediatric Crohn’s Disease Treatment (investing.com)
- Jaguar Health, Inc. (JAGX) is at $0.20 per share and GW Pharmaceuticals plc (GWPH) is listed at $101.49 – Stocks Gallery (stocksgallery.com)
- Analyst’s Buy rated Healthcare Stock: GW Pharmaceuticals plc (GWPH) – Street Observer (press release) (streetobserver.com)
- What Do Zogenix Drug Study Results Mean For GW Pharmaceuticals’ Epidiolex? – Benzinga (benzinga.com)
GW Pharmaceuticals PLC (GWPH) opened at 110.88 on Thursday. The stock’s market capitalization is $2.81 billion. The stock’s 50 day moving average is $105.59 and its 200-day moving average is $108.26. GW Pharmaceuticals PLC has a 12 month low of $92.65 and a 12 month high of $137.88.
GW Pharmaceuticals PLC (NASDAQ:GWPH) last posted its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($2.07) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.73) by ($0.34). The firm had revenue of $3.14 million for the quarter, compared to analyst estimates of $2.10 million. GW Pharmaceuticals PLC had a negative net margin of 1,384.41% and a negative return on equity of 28.80%. During the same period in the prior year, the company posted ($0.05) earnings per share. On average, equities research analysts expect that GW Pharmaceuticals PLC will post ($5.94) earnings per share for the current year.
Several brokerages have commented on GWPH. ValuEngine lowered shares of GW Pharmaceuticals PLC from a “hold” rating to a “sell” rating in a research note on Monday. Cantor Fitzgerald reiterated an “overweight” rating and issued a $208.00 price target on shares of GW Pharmaceuticals PLC in a research note on Monday. Cowen and Company reiterated an “outperform” rating and issued a $165.00 price target on shares of GW Pharmaceuticals PLC in a research note on Monday. Leerink Swann reiterated an “outperform” rating and issued a $153.00 price target (down from $160.00) on shares of GW Pharmaceuticals PLC in a research note on Monday. Finally, Evercore ISI began coverage on shares of GW Pharmaceuticals PLC in a research note on Wednesday, August 16th. They issued an “outperform” rating and a $154.00 price target on the stock. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $149.83.
WARNING: This piece was first published by Watch List News and is the property of of Watch List News. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this piece can be accessed at https://www.watchlistnews.com/gw-pharmaceuticals-plc-gwph-getting-somewhat-favorable-media-coverage-report-shows/1609653.html.
About GW Pharmaceuticals PLC
GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).
Receive News & Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.